Ameriprise
TCRR

Ameriprise’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Ameriprise’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-17,995
Closed -$398K – 3992
2021
Q1 		$398K Buy
17,995
+35
+0.2% +$954 ﹤0.01% 3487
2020
Q4 		$556K Buy
17,960
+1,230
+7% +$31.1K ﹤0.01% 3303
2020
Q3 		$340K Buy
16,730
+4,155
+33% +$73K ﹤0.01% 3386
2020
Q2 		$193K Sell
12,575
-25,560
-67% -$295K ﹤0.01% 3500
2020
Q1 		$295K Sell
38,135
-1,080
-3% -$13.2K ﹤0.01% 3308
2019
Q4 		$560K Sell
39,215
-1,395
-3% -$21.6K ﹤0.01% 3296
2019
Q3 		$610K Sell
40,610
-79,990
-66% -$1.25M ﹤0.01% 3230
2019
Q2 		$1.73M Sell
120,600
-17,196
-12% -$274K ﹤0.01% 2837
2019
Q1 		$2.4M Buy
+137,796
New +$2.44M ﹤0.01% 2654

Other funds holding TCRR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Ameriprise's TCRR Position: Q2 2021 in Review

Ameriprise sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2021, closing a stake of 17,995 shares — an estimated $398K sold.

Ameriprise first reported a position in TCRR in Q1 2019 and held it in 9 quarters. The position peaked at $2.4M in Q1 2019. 119 funds tracked by Wall St. Rank hold TCRR as of Q2 2021.

  • Ameriprise reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Ameriprise sold 17,995 TCR2 Therapeutics Inc. Common Stock shares in Q2 2021, an estimated $398K.
  • Ameriprise first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2019 and held it in 9 quarters.
  • Ameriprise's TCR2 Therapeutics Inc. Common Stock position peaked at $2.4M in Q1 2019.
  • 119 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2021.

Based on Ameriprise's 13F filing for Q2 2021, filed 16 Aug 2021.